NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis
Year: 2015
Type: article
Study design: Observational Study
Abstract: Evidence exists for a potential modulation of inflammasome activity by interferon beta. Here, we investigated the roles of inflammasomes [absent in melanoma 2 (AIM2); NLR family, CARD domain containing 4 (NLRC4); NLR family, pyrin domain containing 1 and 3 (NLRP1 and NLRP3)] and related cytokines (IL1B, IL10, IL18) in the response to interferon beta in patients with relapsing-remitting multiple sclerosis. Ninety-seven patients treated with interferon beta were classified into responders and non-responders according to clinical criteria after 24 months and clinical-radiological criteria after 12 months of treatment. Messenger RNA expression levels of inflammasomes and cytokines were determined by real-time polymerase chain reaction in peripheral blood mononuclear cells collected before treatment with interferon beta. In a subgroup of patients, NLRP3 and IL1B expression was also determined after 3 months (n = 32) and 12 months (n = 20) of interferon beta treatment. A polymorphism located in the NLRP3 gene, rs35829419, was genotyped in 789 multiple sclerosis patients treated with interferon beta. Baseline mRNA expression levels for NLRP3 and IL1B were increased in peripheral blood mononuclear cells from non-responders compared to responders classified according to clinical criteria after 24 months (P = 0.02 and P = 0.001, respectively). No significant differences were observed for other inflammasomes and related cytokines. Differences in NLRP3 and IL1B expression remained significant following a clinical-radiological classification after 12 months (P = 0.007 and P = 0.02, respectively). After treatment with interferon beta, NLRP3 and IL1B expression was increased in responders but unchanged in non-responders. A trend for association was observed between rs35829419 and interferon beta response (pM-H = 0.08). These results point to a role of the NLRP3 inflammasome and its related cytokine IL1B in the response to interferon beta in patients with relapsing-remitting multiple sclerosis.
Source: Brain
DOI: 10.1093/brain/awu388
Authors: Sunny Malhotra, Jordi Río, Elena Urcelay, Ramil Nurtdinov, Marta F Bustamante, Oscar Fernández, Begoña Oliver, Uwe Zettl, David Brassat, Joep Killestein, Jeannette Lechner-Scott, Jelena Drulovic, Andrew Chan, Filippo Martinelli-Boneschi, Antonio García-Merino, Xavier Montalban, Manuel Comabella
Institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, Hospital Clínico San Carlos, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, University of Rostock, Université Toulouse III - Paul Sabatier, Inserm, Hôpital Purpan, Université de Toulouse, Amsterdam UMC Location Vrije Universiteit Amsterdam, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle Australia, University of Belgrade, St. Josef-Hospital, Ruhr University Bochum, IRCCS Ospedale San Raffaele, Hospital Universitario Puerta de Hierro Majadahonda
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2026694335
